Major Protein of Carcinoembryonic Antigen Gene Family - CD66c, A Novel Marker in Colon Carcinoma

Nataraj, Suma M; Prema, Chaitra Linganna; Vimalambike, Manjunath Gubbanna; Shivalingaiah, Sheeladevi Chandakavadi; Sundaram, Shivakumar; Kumar, Ashwini Prem; Math, Ananda Kuruvatti; Prashant, Akila

doi:10.7860/jcdr/2016/17180.7286

Cited by 5 publications

(3 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…El Attar, (2005) and Sakr et al, (2016) told that the median age of CRC patients in Egypt was 48 and 51.2 ys respectively (5,10) . Basu et al, (2016) and Nataraj et al, (2016) found the mean age of their assessed Indian patients was 52.8 ± 13.5 and 49.31 ys, respectively (11,12) . On the other hand; (13) found that the mean age of their assessed American Non-Hispanic white and American Asian patients was 70.3ys and 66.3ys respectively.…”

Section: Discussionmentioning

confidence: 94%

Untitled

2017

IOSRJPBS

View full text Add to dashboard Cite

Introduction: Colorectal cancer (CRC) represents the 3 rd most common tumor worldwide and the 6 th in Egypt. It is still burdened by significant morbidity and mortality despite several therapeutic improvements. A gold standard for early detection and non invasive diagnosis is lacking. Aim was to assess faecal tumor M2-PK™ (ScheBo test) for detection of CRC.ln Adult Egyptians Methods: This cross-sectional, case-control study was carried out on 66 subjects. The cases group comprised 46 consecutive treatment-naïve patients with sporadic CRC proved by colonoscopy, histopathology and abdominal computed tomography which all together helped in tumor staging with TNM and Duke's staging systems. Twenty apparently healthy subjects (without CRC and with normal colonoscopy) served as the control group (age and sex matching the cases group). Faecal tumor M2-PK™ (ScheBo test) was assessed in all the study subjects. Results: Cases were 24 males and 22 females with a mean age of 50.6 y s and the range was 22-81y s. Age ditribution showed 12 cases (26%) below 40 and 50% above 50 y s. Bleeding per rectum was the main presenting symptom (39%) followed by recent onset constipation (34.8%) in the studied cases. Rectal lesions were found during colonoscopy in 47.8% of cases while colonic lesions were found in 52.2%. Mass was the most encountered gross pathology (in 67.4%, 31 cases) followed by ulcer (in 28.3%, 13 cases) and stricture (in 4.3%, 2 cases). Adenocarcinoma was the commonest type (76.1 %, 35 cases) followed by mucinous adenocarcinoma (15.2 %, 7 cases). The fecal levels of tumor M2-PK were significantly higher (P<0.001) in cases compared to the control (35.66 ± 17.32 and 2.74 ± 4.36 U/ml, respectively). Fecal tumor M2-PK levels showed a significant positive correlation with both TNM and Duke's stages (p˂0.05), while no significant correlation was found with age and sex. Applying ROC curve, at a cutoff value of 3.9 U/ml, fecal Tumor M2-PK was 97.8% sensitive and 85% specific for detection of CRC with AUROC = 0.96. Conclusion: Fecal tumor M2-PK was a sensitive and specific marker for detection of CRC at values ≥ 3.9 U/ml and positively correlated with the tumour grade and stage.

show abstract

Section: Discussionmentioning

confidence: 94%

Untitled

2017

IOSRJPBS

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Fecal Tumor M2-Pyruvate Kinase ™ (ScheBo Test) for Colorectal Cancer Detection in Adult Egyptians

Lashin¹

2017

IOSRJPBS

View full text Add to dashboard Cite

show abstract

“…Colorectal cancer (CRC) is the third most common cause of death worldwide (1-5). CRC incidence rate has increased in developing countries, including Iran and other Asian countries, due to changes related to culture and eating habits (3, 6-9). In most patients with colorectal cancer, the disease is asymptomatic at early stages; thus, many screening tools and molecular biomarkers are developed to detect colorectal cancer in early stages.…”

Section: Introductionmentioning

confidence: 99%

Dkk-3 as a potential biomarker for diagnosis and prognosis of colorectal cancer

Safari

Mosayebi

Khorram

2018

Med. J. Islam. Repub. Iran

View full text Add to dashboard Cite

Background: The Dickkopf 3 (Dkk-3) protein is a member of the Dkk family known as Wnt signaling inhibitor. The level of DKk-3 changes in a wide range of cancers, such as colorectal cancer, lung cancer, prostate cancer, and bladder cancer, is proposed as a biomarker for diagnosis and prognosis of many cancers. The present study was conducted to evaluate the serum level of Dkk-3 as a cancer biomarker and to determine their prognostic value in colorectal cancer (CRC) patients and healthy matched controls. Methods: A total of 30 colorectal cancer patients at different stages of the disease and healthy matched controls with no history of inflammatory and autoimmune disease or cancer were enrolled in the study. The level of Dkk-3 was assessed serologically using enzymelinked immunosorbent assay (ELISA) method, moreover, relevance of these markers with patients’ clinicopathological features was subsequently assessed. Means comparison and ROC curves analysis were done using SPSS software. P-value ˂0.05 was considered significant in all the tests. Results: In this study, it was revealed that serum level of Dkk-3 was significantly (p<0.001) lower in patients compared to the healthy controls. Statistical analysis showed that serum level of Dkk-3 has 78% specificity and 77% sensitivity (AUC= 0.782, 95% CI) for diagnosis of colorectal cancer. Conclusion: Dkk-3 protein can be considered as a potential biomarker for diagnosis and possibly the prognosis of colorectal cancer.

show abstract

Major Protein of Carcinoembryonic Antigen Gene Family - CD66c, A Novel Marker in Colon Carcinoma

Cited by 5 publications

References 19 publications

Untitled

Untitled

Fecal Tumor M2-Pyruvate Kinase ™ (ScheBo Test) for Colorectal Cancer Detection in Adult Egyptians

Dkk-3 as a potential biomarker for diagnosis and prognosis of colorectal cancer

Contact Info

Product

Resources

About